Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-456-2382
Fax+1 214-456-6133
Dr. Voit is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Richard Voit, MD, is a pediatric hematology and oncology specialist based in Dallas, TX. He completed his medical education at the University of Texas Southwestern Medical School and his pediatrics residency at Boston Children's Hospital/Boston Medical Center. His research focuses on gene therapy and hematopoietic cell regulation, with several publications in prominent journals such as Cell Stem Cell, Journal of Clinical Immunology, Haematologica, Blood Advances, and Nature Immunology. His work has been cited by other researchers, indicating engagement with the scientific community.
Education & Training
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2014 - 2017
University of Texas Southwestern Medical SchoolClass of 2014
Certifications & Licensure
TX State Medical License 2024 - 2026
MA State Medical License 2014 - 2025
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 4 citationsRegulated GATA1 expression as a universal gene therapy for Diamond-Blackfan anemia.Richard A Voit, Xiaotian Liao, Alexis Caulier, Mateusz Antoszewski, Blake Cohen
Cell Stem Cell. 2025-01-02 - CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.Travis J Fleming, Mateusz Antoszewski, Sander Lambo, Michael C Gundry, Riccardo Piussi
Biorxiv. 2024-12-30 - 2 citationsGene therapy for congenital marrow failure syndromes - no longer grasping at straws?Richard A Voit, Seth J Corey
Haematologica. 2023-11-01
Press Mentions
A Universal Gene Therapy for Diamond-Blackfan Anemia Is Poised for Clinical TestingNovember 21st, 2024
Universal Gene Therapy for Blood Disorders Targets Downstream PathwaysNovember 14th, 2024
Grant Support
- Uncovering therapeutic vulnerabilities in AML through mechanistic interrogation of MECOM activityBOSTON CHILDREN'S HOSPITAL2024–2029
- Uncovering therapeutic vulnerabilities in AML through mechanistic interrogation of MECOM activityBOSTON CHILDREN'S HOSPITAL2024–2029
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
